Previous close | 338.93 |
Open | 350.50 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 350.50 - 352.00 |
52-week range | 350.50 - 352.00 |
Volume | |
Avg. volume | N/A |
Market cap | 25.113B |
Beta (5Y monthly) | 0.35 |
PE ratio (TTM) | 106.38 |
EPS (TTM) | 3.31 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
FRANKFURT (Reuters) -Franco-German lab supplies group Sartorius AG stuck to its 2022 outlook on Thursday as demand remained strong in the first quarter despite uncertainties from the war in Ukraine. Sartorius, which competes in bioreactor gear with Merck KGaA and Thermo Fisher, said underlying earnings before interest, taxes, depreciation and amortisation (EBITDA) had increased by nearly a third from the same quarter last year to reach 349 million euros ($378.28 million). The corresponding underlying EBITDA margin improved to 34.1%, said the company which last year entered Germany's blue-chip index DAX.
(Reuters) -Laboratory supplies vendor Sartorius AG has approached Maravai LifeSciences Holdings Inc, a U.S. provider of capping reagents for COVID-19 vaccines, with an $11 billion acquisition offer, people familiar with the matter said. Maravai rejected the $42 per share all-cash offer from Goettingen, Germany-based Sartorius earlier this month as inadequate, the sources said. It is not clear whether Sartorius will return with a new offer or whether Maravai will attract acquisition interest from other laboratory equipment and supplies providers.
MILFORD, Mass. & GOETTINGEN, Germany, October 27, 2021--Waters and Sartorius Partner to Help Bioprocess Scientists Accelerate Clone Selection and Process Development